Is identification of β-glucosidase 1 as a biomarker and its high expression in hepatocellular carcinoma associated with resistance to chemotherapy drugs?
Our data support β-glucosidase 1 as a HCC biomarker due to its prognosis significance.
Body mass index and WC were independently associated with CVD risk factors. There were differences in the gender-specific relevance of measures of body fat distribution in assessing the insulin resistance, β-cell function and thus the risk of diabetes. Therefore, WC should be measured in addition to BMI to assess CVD risk accurately and implement efficient treatment strategies.